Sign in to fuzzto save your conversations, follow your research and come back anytime.
Camlin Fine Sciences
CAMLINFINE
NSE
BSE
NSEBSESectorChemicals
102.28
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Revenue rebounds strongly across segments, but rising costs and margin compression keep profits in the red.
Consolidated revenue grew from ₹4,248 Cr in Q4 FY26 to ₹5,199 Cr in Q1 FY27, signaling strong top-line momentum.
Consolidated EBITDA margin dropped from 5.0% in Q4 FY26 to 1.8% in Q1 FY27, signaling critical cost control failures.
Specialty Ingredients revenue rose from ₹3,414 Cr in Q4 FY26 to ₹4,013 Cr in Q1 FY27, confirming robust segment expansion.
Consolidated profit after tax swung from ₹9.8 Cr in Q4 FY26 to a loss of ₹318 Cr in Q1 FY27, confirming severe profitability distress.
Performance Chemicals revenue surged from ₹327 Cr in Q4 FY26 to ₹1,749 Cr in Q1 FY27, reflecting major new contract wins.
Consolidated employee cost grew from ₹659 Cr in Q4 FY26 to ₹734 Cr in Q1 FY27, indicating rising fixed wage burdens.
Consolidated finance cost fell from ₹230 Cr in Q4 FY26 to ₹140 Cr in Q1 FY27, suggesting debt restructuring benefits.
Consolidated other expenses climbed from ₹1,189 Cr in Q4 FY26 to ₹1,315 Cr in Q1 FY27, pressuring overall cost efficiency.
Aroma Ingredients revenue rebounded from ₹466 Cr in Q4 FY26 to ₹774 Cr in Q1 FY27, indicating strong demand recovery.
Consolidated adjusted EBITDA fell from ₹212 Cr in Q4 FY26 to ₹176 Cr in Q1 FY27, reflecting sustained profitability pressure.
